{"id":18379,"date":"2021-06-24T10:43:38","date_gmt":"2021-06-24T14:43:38","guid":{"rendered":"https:\/\/medicarereport.org\/?p=18379"},"modified":"2021-06-24T10:43:38","modified_gmt":"2021-06-24T14:43:38","slug":"a-crucial-overlooked-question-on-the-new-alzheimers-drug-when-should-patients-stop-taking-it","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=18379","title":{"rendered":"A crucial, overlooked question on the new Alzheimer\u2019s drug: When should patients stop taking it?"},"content":{"rendered":"<p>(By Megan Molteni for ST<em>A<\/em>T)<\/p>\n<p>For families and physicians grappling with the historic approval this month of the controversial Alzheimer\u2019s drug Aduhelm, there\u2019s no shortage of unanswered questions. But a critical one has largely been overlooked: Once patients start taking the medication, how will they know when it\u2019s time to stop?\u00a0 Continue reading the article <a href=\"https:\/\/www.statnews.com\/2021\/06\/24\/a-crucial-overlooked-question-on-the-new-alzheimers-drug-when-should-patients-stop-taking-it\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Megan Molteni for STAT) For families and physicians grappling with the historic approval this month of the controversial Alzheimer\u2019s<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,15],"tags":[],"class_list":["post-18379","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18379"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18379\/revisions"}],"predecessor-version":[{"id":18380,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18379\/revisions\/18380"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}